Clinical trials: terminated
Alpha-1 Antitrypsin Deficiency
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
The purpose of the study is to determine the safety and tolerability of escalating doses of ARC-AAT and to evaluate the pharmacokinetics of ARC-AAT and the effect of ARC-AAT on circulating levels of alpha-1 antitrypsin (AAT).
- Trial name
- NCT02363946
- Testing
- ARC-AAT Injection, Diphenhydramine
- Where
- 4 sites in Australia, Germany and 2 more
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Triple-negative Breast Cancer
Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy
This is a randomized, open-label, adaptive, two arm, multicentre, Phase II trial comparing a neoadjuvant chemotherapy with PDL1-inhibition (Atezolizumab) and Atezolizumab two-week window to chemotherapy with PDL1-inhibition…
- Trial name
- neoMono (NCT04770272)
- Testing
- Atezolizumab 840 MG in 14 ML Injection, Atezolizumab 1200 MG in 20 ML Injection, Carboplatin
- Where
- Germany
- Volunteers
- 442 people
- Sponsor
- Palleos Healthcare GmbH
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Hepatic Insufficiency, Neoplasms
A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies
The purpose of this study is to evaluate the effect of moderate or severe liver impairment on the drug levels of oral azacitidine and the safety and tolerability of oral azacitidine in participants with myeloid malignancies.
- Trial name
- NCT05209295
- Testing
- Onureg
- Where
- 18 sites in United States, Argentina and 3 more
- Volunteers
- 2 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
The purpose of this study is to evaluate the efficacy and safety of telitacicept in the treatment of moderately to severely active SLE.
- Trial name
- NCT05306574
- Testing
- Telitacicept
- Where
- 78 sites in United States, Argentina and 13 more
- Volunteers
- 91 people
- Sponsor
- Vor Biopharma
Advanced Endometrial Cancer, Sarcoma of Uterus
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
This clinical study plans to enroll 69 endometrial cancer patients and 5-10 uterine sarcoma patients. The trial is divided into a lead-in phase and a main phase.
- Trial name
- NCT05481645
- Testing
- TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection
- Where
- 11 sites in China
- Volunteers
- 71 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Ovarian Neoplasms, Peritoneal Neoplasms
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
The purpose of the study is to test the safety of the medicine called Felmetatug Vedotin alone and with pembrolizumab in participants with solid tumors. It will also look at the side effects of this medicine.
- Conditions
- Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms
- Trial name
- NCT05194072
- Testing
- Felmetatug Vedotin, Pembrolizumab
- Where
- 27 sites in United States, Canada and 3 more
- Volunteers
- 250 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Non-Small-Cell Lung
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study.
- Trial name
- NCT04585815
- Testing
- Sasanlimab Prefilled syringe, Encorafenib, Binimetinib
- Where
- 55 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Cancer of Ovary, Pancreatic Ductal Adenocarcinoma
Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy
This multicenter Phase 2a study was designed to evaluate the safety, tolerability, and efficacy of Promitil in patients with recurrent ovarian cancer and inoperable, locally advanced or metastatic pancreatic cancer, which bears…
- Trial name
- NCT06478862
- Testing
- Promitil
- Where
- 6 sites in Israel
- Volunteers
- 19 people
- Sponsor
- Lipomedix Pharmaceuticals Inc.
Advanced Solid Tumor
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors
An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of APG-1387 in combination with toripalimab. A phase II study of 3 cohorts will be included.
- Trial name
- NCT04284488
- Testing
- APG-1387 for Injection, Toripalimab
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Ascentage Pharma Group Inc.
Airway Control
Observational Study of Rapid Sequence Intubation Drug Delivery Using Intraosseous and Intravenous Access.
This study will evaluate using intraosseous vascular access and intravenous vascular access to give patients the necessary medications to perform rapid sequence intubation, for patients with airway difficulties.
- Trial name
- NCT01486407
- Where
- 2 sites in United States
- Volunteers
- 4 people
- Sponsor
- Vidacare Corporation
Renal Insufficiency, Chronic, Hyperkalemia
A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
The purpose of this study is to evaluate the effect of Sodium Zirconium Cyclosilicate (SZC), as adjunct to ACEi/ARB therapy (lisinopril or valsartan), on slowing CKD progression (assessed as the reduction in participant's…
- Trial name
- STABILIZE-CKD (NCT05056727)
- Testing
- Sodium Zirconium Cyclosilicate (SZC), Lisinopril, Valsartan
- Where
- 276 sites in United States, Argentina and 19 more
- Volunteers
- 1,112 people
- Sponsor
- AstraZeneca
Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia
CX-4945 in Viral Community Acquired Pneumonia
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated…
- Conditions
- Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia
- Trial name
- NCT06202521
- Testing
- CX-4945 (SARS-CoV-2 domain), CX-4945 (Influenza virus domain)
- Where
- 7 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Senhwa Biosciences, Inc.
Venous Insufficiency, Venous Leg Ulcer
PICO Venous Leg Ulcers (VLU) Reimbursement Study
This study intends to demonstrate the superiority of PICO treatment when applied up to 12 weeks, versus Standard of Care (SOC) in the treatment of hard to heal Venous Leg Ulcers (VLU) by community-based practitioners.
- Trial name
- NCT06510777
- Testing
- PICO Treatment, Standard of Care (SOC) Treatment
- Where
- 44 sites in France
- Volunteers
- 142 people
- Sponsor
- Smith & Nephew, Inc.
Sickle Cell Disease
Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)
This study evaluated a genome-edited, autologous, hematopoietic stem and progenitor cell (HSPC) product - OTQ923 to reduce the biologic activity of BCL11A, increasing fetal hemoglobin (HbF) and reducing complications of sickle…
- Trial name
- NCT04443907
- Testing
- OTQ923
- Where
- 3 sites in United States
- Volunteers
- 4 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer, Castration Resistant Prostate Cancer
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).
- Conditions
- Prostate Cancer, Castration Resistant Prostate Cancer, Prostatic Neoplasms
- Trial name
- NCT01995058
- Testing
- cabozantinib, abiraterone, prednisone
- Where
- 20 sites in United States
- Volunteers
- 54 people
- Sponsor
- Exelixis
Advanced Pancreatic Cancer
APG-1387 Plus Chemotherapy in Advanced Pancreatic Adenocarcinoma
This study is a two stage study consisting of a dose escalation phase Ib and a phase II study which include subjects with previously-treated, advanced pancreatic adenocarcinoma.
- Trial name
- NCT04643405
- Testing
- APG-1387 for Injection, Gemcitabine, Nab paclitaxel
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Ascentage Pharma Group Inc.
Melanoma
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
- Trial name
- RELATIVITY-098 (NCT05002569)
- Testing
- Nivolumab, Nivolumab + Relatlimab Fixed Dose Combination
- Where
- 184 sites in United States, Argentina and 23 more
- Volunteers
- 1,093 people
- Sponsor
- Bristol-Myers Squibb
Blepharitis
A Phase 3 Study to Evaluate the Efficacy and Safety of Pimecrolimus 0.3% Ophthalmic Ointment
The objective of this study is to determine the efficacy and safety of Pimecrolimus 0.3% (MR-139) Ophthalmic Ointment.
- Trial name
- NCT06400511
- Testing
- Pimecrolimus 0.3% Ophthalmic Ointment
- Where
- 29 sites in United States
- Volunteers
- 477 people
- Sponsor
- Famy Life Sciences, a Viatris Company
Advanced Soft-tissue Sarcoma, Advanced Epithelioid Sarcoma
Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma
The participants of this study will have advanced epithelioid sarcoma. Sarcoma is a cancer of the connective tissues, such as nerves, muscles and bones. Epithelioid sarcoma is an ultra-rare sarcoma of the soft-tissue.
- Trial name
- NCT04204941
- Testing
- Tazemetostat, Doxorubicin HCl
- Where
- 21 sites in United States, Canada and 2 more
- Volunteers
- 25 people
- Sponsor
- Epizyme, Inc.